178 patents
Page 2 of 9
Utility
Preventive Treatment of Migraine
12 Oct 23
The present disclosure provides medicaments and methods for the preventive treatment of migraine, particularly the preventive or prophylactic treatment of chronic migraine.
Joel Trugman, Michelle Finnegan
Filed: 9 Mar 23
Utility
Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
5 Oct 23
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations.
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
Filed: 14 Apr 23
Utility
Botulinum Neurotoxin for Treatment of Disorders Associated with Melanocyte Hyperactivity And/or Excess Melanin
28 Sep 23
Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided.
Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsia
Filed: 21 Dec 22
Utility
Opioid Receptor Modulator Dosage Formulations
21 Sep 23
Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.
Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
Filed: 26 May 23
Utility
Glaucoma Treatment Via Intracameral Ocular Implants
14 Sep 23
The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat intraocular conditions.
Tomas Navratil, Sanjib Das, Andres Garcia, Janet Tully
Filed: 11 Aug 22
Utility
Biodegradable ALPHA-2 Agonist Polymeric Implants and Therapeutic Uses Thereof
14 Sep 23
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time.
Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
Filed: 15 Jul 22
Utility
Microneedle Arrays Formed from Polymer Films
7 Sep 23
An active agent can be administered transdermally to a patient by using a transdermal patch that has microneedles that are compositionally homogenous with a base layer.
Roger L. KASPAR, Tycho Speaker
Filed: 9 Nov 22
Utility
Coacervate Hyaluronan Hydrogels for Dermal Filler Applications
7 Sep 23
The present disclosure provides dermal fillers comprising hyaluronic acid-based hydrogels.
Futian Liu, Xiaojie Yu, Dennis E. Van Epps, Iossif A. Strehin
Filed: 11 Oct 22
Utility
Immuno-based Botulinum Toxin Serotype a Activity Assays
7 Sep 23
The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.
Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
Filed: 29 Sep 22
Utility
Compositions Comprising Tropoelastin Crosslinked to Hyaluronic Acid and the Methods of Use Thereof
17 Aug 23
Soft tissue conditions can be treated by administering a composition comprising tropoelastin including, for example, a composition comprising tropoelastin crosslinked to hyaluronic acid to increase moisture content in the soft tissue.
Robert DANIELS, Christopher K. HEE, Anthony S. WEISS, Michal Graff MITZMACHER, Suzanne M. MITHIEUX
Filed: 14 May 21
Utility
Formulations of Biologics for Intravesical Instillation
17 Aug 23
Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence J. Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas, Catherine Rheaume
Filed: 16 Sep 22
Utility
Formulations of Biologics for Intravesical Instillation
17 Aug 23
Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
Eric A. Forssen, Patrick M. Hughes, David C. Rupp
Filed: 26 Sep 22
Utility
Tissue Expansion Device with Fluid Collection
10 Aug 23
A tissue expander can be configured to collect extracellular fluid from within a patient’s body cavity.
David J. Schuessler
Filed: 9 Jul 21
Utility
Treatment of migraine
8 Aug 23
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant.
Joel Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Filed: 22 Dec 21
Utility
Macrogol 15 Hydroxystearate Formulations
3 Aug 23
Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.
Anuradha V. Gore, Kevin S. Warner, Chetan P. Pujara, Richard S. Graham, Ajay P. Parashar, Mu-Lan Lee, Robert S. Jordan, Sukhon Likitlersuang
Filed: 5 Apr 23
Utility
Methods and Compositions for Categorizing And/or Treating Chin Retrusion In a Subject In Need Thereof
3 Aug 23
The disclosure provides methods and compositions for treating or categorizing chin retrusion in a subject such as an East Asian subject.
Jiazhi Qu, Yi Jia, Dong Li
Filed: 17 Jun 21
Utility
Immuno-based Botulinum Toxin Serotype a Activity Assays
27 Jul 23
The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.
Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
Filed: 17 Aug 22
Utility
Methods of treatment using a syringe extrusion accessory
27 Jun 23
A method of treatment may include providing a syringe having medicinal fluid therein for administering to a patient and coupling an attachment portion of an extrusion accessory having a handle and a pawl to a flange portion of the syringe.
Ethan W. Franklin, Justin J. Schwab
Filed: 12 Jul 19
Utility
CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
25 May 23
Methods for treating neurological or neuropsychiatric disorder and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.
Mitchell F. Brin, Andrew M. Blumenfeld
Filed: 27 Jun 22
Utility
Clostridial Toxin - Hyaluronic Acid Compositions
25 May 23
Pharmaceutical compositions that extend the effect and duration of a Clostridial toxin active ingredient are described.
Cindy WU, James Cunningham, Marianne Do, Ron Broide
Filed: 30 Jun 22